Pinned post
Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026, providing further evidence on exploratory efficacy endpoints supporting progression to later stage development:
infextx.com/infex-therapeu…
infextx.com/infex-therapeu…